Androgen receptor gene rearrangements: New perspectives on prostate cancer progression

Lucas J. Brand, Scott M. Dehm

Research output: Contribution to journalReview article

23 Scopus citations

Abstract

The androgen receptor (AR) is a master regulator transcription factor in normal and cancerous prostate cells. Canonical AR activation requires binding of androgen ligand to the AR ligand binding domain, translocation to the nucleus, and transcriptional activation of AR target genes. This regulatory axis is targeted for systemic therapy of advanced prostate cancer. However, a new paradigm for AR activation in castration-resistant prostate cancer (CRPC) has emerged wherein alternative splicing of AR mRNA promotes synthesis of constitutively active AR variants that lack the AR ligand binding domain (LBD). Recent work has indicated that structural alteration of the AR gene locus represents a key mechanism by which alterations in AR mRNA splicing arise. In this review, we examine the role of truncated AR variants (ARVs) and their corresponding genomic origins in models of prostate cancer progression, as well as the challenges they pose to the current standard of prostate cancer therapies targeting the AR ligand binding domain. Since ARVs lack the COOH-terminal LBD, the genesis of these AR gene rearrangements and their resulting ARVs provides strong rationale for the pursuit of new avenues of therapeutic intervention targeted at the AR NH2-terminal domain. We further suggest that genomic events leading to ARV expression could act as novel biomarkers of disease progression that may guide the optimal use of current and next-generation AR-targeted therapy.

Original languageEnglish (US)
Pages (from-to)441-449
Number of pages9
JournalCurrent Drug Targets
Volume14
Issue number4
DOIs
StatePublished - 2013

Keywords

  • Alternative splicing
  • Androgen receptor
  • Castration resistance
  • Genomic rearrangement
  • Prostate cancer

Fingerprint Dive into the research topics of 'Androgen receptor gene rearrangements: New perspectives on prostate cancer progression'. Together they form a unique fingerprint.

  • Cite this